Targeted radioactive antibody therapy combined with other treatments for B‑cell lymphoma
Radioimmunotherapy Combinations for B-cell Malignancy
This work aims to use antibody drugs carrying radiation together with other therapies to better eliminate relapsed or hard‑to‑treat B‑cell non‑Hodgkin lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project ID | NIH-11006275 on NIH RePORTER |
What this research studies
If you joined, doctors would give antibodies that stick to B‑cell lymphoma cells and carry a radioactive particle so the radiation is delivered directly to the tumor, and they would combine this with other treatments such as high‑dose therapy and stem‑cell support. They plan to test different radioactive isotopes (for example yttrium‑90 or astatine) and ways to improve the amount of radiation that reaches tumor versus normal tissue. Participants would have blood tests, imaging, and follow‑up visits to track tumor response, side effects, and long‑term remission. Lab studies on tumor or blood samples may also be done to understand why some cancers come back and how to prevent that.
Who could benefit from this research
Good fit: Ideal candidates are patients with relapsed or refractory B‑cell non‑Hodgkin lymphoma who have exhausted standard treatments and are medically eligible for radioimmunotherapy and possible stem‑cell support.
Not a fit: People with non‑B‑cell cancers, those too frail for intensive therapy, or whose tumors do not express the antibody target (CD20) are unlikely to benefit.
Why it matters
Potential benefit: If successful, this approach could raise cure rates and lower relapse risk for people with relapsed or refractory B‑cell non‑Hodgkin lymphoma.
How similar studies have performed: Previous radioimmunotherapy given at very high doses with stem‑cell rescue has produced high remission rates in some heavily treated lymphoma patients, but relapse and toxicity remain challenges, so combination approaches are promising but not yet proven.
Where this research is happening
Coral Gables, United States
- University of Miami School of Medicine — Coral Gables, United States (Active)
Researchers
- Principal investigator: Green, Damian J. — University of Miami School of Medicine
- Study coordinator: Green, Damian J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.